CA2933601A1 - Angiotensin ii alone or in combination for the treatment of hypotension - Google Patents

Angiotensin ii alone or in combination for the treatment of hypotension Download PDF

Info

Publication number: CA2933601A1
Authority: CA; Canada
Prior art keywords: dose; angiotensin; catecholamine; norepinephrine; mcg
Prior art date: 2013-12-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA2933601A

Other languages

English (en)

French (fr)

Inventor

Lakhmir Chawla

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

George Washington University

Original Assignee

George Washington University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-18

Filing date

2014-12-18

Publication date

2015-06-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2933601(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-18 Application filed by George Washington University filed Critical George Washington University

2015-06-25 Publication of CA2933601A1 publication Critical patent/CA2933601A1/en

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2933601A 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension Pending CA2933601A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201361917576P	2013-12-18	2013-12-18
US61/917,576		2013-12-18
US201461955706P	2014-03-19	2014-03-19
US61/955,706		2014-03-19
PCT/US2014/071186 WO2015095535A1 (en)	2013-12-18	2014-12-18	Angiotensin ii alone or in combination for the treatment of hypotension

Publications (1)

Publication Number	Publication Date
CA2933601A1 true CA2933601A1 (en)	2015-06-25

Family

ID=53367119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2933601A Pending CA2933601A1 (en)	2013-12-18	2014-12-18	Angiotensin ii alone or in combination for the treatment of hypotension

Country Status (25)

Country	Link
US (7)	US9220745B2 (2)
EP (2)	EP2986308B1 (2)
JP (4)	JP6824739B2 (2)
KR (4)	KR20230051721A (2)
CN (4)	CN111920939A (2)
AU (3)	AU2014364528C1 (2)
BR (1)	BR112016013961A2 (2)
CA (1)	CA2933601A1 (2)
CY (1)	CY1122604T1 (2)
DK (2)	DK3607962T3 (2)
EA (1)	EA037823B1 (2)
ES (2)	ES2771749T3 (2)
FI (1)	FI3607962T3 (2)
HR (2)	HRP20200009T1 (2)
HU (1)	HUE047062T2 (2)
IL (1)	IL246162B (2)
LT (2)	LT2986308T (2)
MX (2)	MX380968B (2)
NZ (1)	NZ721089A (2)
PL (2)	PL3607962T3 (2)
PT (2)	PT3607962T (2)
RS (2)	RS59804B1 (2)
SI (2)	SI3607962T1 (2)
SM (2)	SMT202000018T1 (2)
WO (1)	WO2015095535A1 (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9572856B2 (en)	2009-12-16	2017-02-21	The George Washington University a Congressionally Chartered Not-for-Profit Corporation	Method of treating low blood pressure
RS59804B1 (sr)	2013-12-18	2020-02-28	The George Washington University A Congressionally Chartered Not For Profit Corporation	Angiotenzin ii u kombinaciji za lečenje hipotenzije
CA2954016A1 (en) *	2014-07-08	2016-01-14	La Jolla Pharma, Llc	Methods for treating hypotension
WO2016153558A1 (en)	2015-03-20	2016-09-29	Atkinson Arthur J	Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
EP3400000B1 (en) *	2016-01-07	2023-12-06	La Jolla Pharma, LLC	Methods for administering angiotensin ii
KR20180108630A (ko) *	2016-01-07	2018-10-04	라 졸라 파마슈티칼 컴파니	혈관수축제의 투여 방법
US11583568B2 (en)	2017-04-14	2023-02-21	La Jolla Pharma, Llc	Methods for administering angiotensin II
US20190183962A1 (en) *	2017-12-15	2019-06-20	La Jolla Pharma, Llc	Angiotensin compositions and methods related thereto
WO2023244552A1 (en) *	2022-06-15	2023-12-21	Virginia Commonwealth University	Methods for fluid resuscitation of an organ donor
EP4633658A1 (en) *	2022-12-12	2025-10-22	Proletariat Therapeutics, Inc.	Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU181008B (en)	1980-01-18	1983-05-30	Richter Gedeon Vegyeszet	Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en)	1989-09-13	1993-06-01	Board Of Regents, The University Of Texas System	Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en)	1993-08-30	1995-08-22	Merck & Co., Inc.	Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US6592865B2 (en)	2001-06-04	2003-07-15	Human Genome Sciences, Inc.	Methods and compositions for modulating ACE-2 activity
US7115266B2 (en)	2001-10-05	2006-10-03	Cytos Biotechnology Ag	Angiotensin peptide-carrier conjugates and uses thereof
NO20034952D0 (no)	2003-11-06	2003-11-06	Amersham Health As	Farmasöytiske forbindelser
EP1699495A2 (en)	2003-11-06	2006-09-13	Amersham Health AS	Conjugates of angiotensin ii and an imaging moiety
FR2880807B1 (fr) *	2005-01-19	2007-04-13	Aguettant Sa Lab	Composition pharmaceutique injectable
DE602006021600D1 (de)	2005-09-29	2011-06-09	Fibrogen Inc	Verfahren zur senkung des blutdrucks
CN101351215A (zh) *	2005-12-30	2009-01-21	霍华德·弗洛里实验生理学及医学研究所	治疗方法
US20070293552A1 (en)	2006-06-15	2007-12-20	Gorczynski Richard J	Antihypertensive therapy method
WO2008130217A1 (en) *	2006-08-08	2008-10-30	Applied Nanosystems B.V.	Cyclic angiotensin analogs
CN101795675A (zh)	2006-11-17	2010-08-04	达沃尔泰拉公司	使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
WO2009009907A1 (en) *	2007-07-18	2009-01-22	The University Of British Columbia	Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) *	2008-09-09	2010-03-10	Rijksuniversiteit te Groningen	Oxytocin formulations and uses thereof
WO2010062896A1 (en)	2008-11-28	2010-06-03	Abbott Laboratories	Stable antibody compositions and methods for stabilizing same
US9572856B2 (en)	2009-12-16	2017-02-21	The George Washington University a Congressionally Chartered Not-for-Profit Corporation	Method of treating low blood pressure
FR2959414B1 (fr) *	2010-04-30	2016-01-08	Luc Quintin	Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
WO2012009545A1 (en)	2010-07-14	2012-01-19	Cumberland Emerging Technologies, Inc	Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
CN105592855A (zh)	2013-04-26	2016-05-18	拉卓拉药物公司	用于治疗肾衰竭的组合物和方法
RS59804B1 (sr)	2013-12-18	2020-02-28	The George Washington University A Congressionally Chartered Not For Profit Corporation	Angiotenzin ii u kombinaciji za lečenje hipotenzije
US20150286797A1 (en)	2014-04-02	2015-10-08	David R. Ratto	System and method for administering medication
CA2954016A1 (en)	2014-07-08	2016-01-14	La Jolla Pharma, Llc	Methods for treating hypotension
KR20180108630A (ko)	2016-01-07	2018-10-04	라 졸라 파마슈티칼 컴파니	혈관수축제의 투여 방법
EP3400000B1 (en)	2016-01-07	2023-12-06	La Jolla Pharma, LLC	Methods for administering angiotensin ii
US11583568B2 (en)	2017-04-14	2023-02-21	La Jolla Pharma, Llc	Methods for administering angiotensin II
US20190183962A1 (en)	2017-12-15	2019-06-20	La Jolla Pharma, Llc	Angiotensin compositions and methods related thereto

2014
- 2014-12-18 RS RS20200021A patent/RS59804B1/sr unknown
- 2014-12-18 PL PL19197866.7T patent/PL3607962T3/pl unknown
- 2014-12-18 DK DK19197866.7T patent/DK3607962T3/da active
- 2014-12-18 PT PT191978667T patent/PT3607962T/pt unknown
- 2014-12-18 EA EA201691258A patent/EA037823B1/ru unknown
- 2014-12-18 MX MX2016008108A patent/MX380968B/es unknown
- 2014-12-18 CN CN202010824424.5A patent/CN111920939A/zh active Pending
- 2014-12-18 SM SM20200018T patent/SMT202000018T1/it unknown
- 2014-12-18 LT LTEP14872684.7T patent/LT2986308T/lt unknown
- 2014-12-18 WO PCT/US2014/071186 patent/WO2015095535A1/en not_active Ceased
- 2014-12-18 CN CN202411722811.2A patent/CN119700926A/zh active Pending
- 2014-12-18 ES ES14872684T patent/ES2771749T3/es active Active
- 2014-12-18 AU AU2014364528A patent/AU2014364528C1/en active Active
- 2014-12-18 FI FIEP19197866.7T patent/FI3607962T3/fi active
- 2014-12-18 CN CN201480075899.1A patent/CN106061493A/zh active Pending
- 2014-12-18 EP EP14872684.7A patent/EP2986308B1/en active Active
- 2014-12-18 HR HRP20200009TT patent/HRP20200009T1/hr unknown
- 2014-12-18 PT PT148726847T patent/PT2986308T/pt unknown
- 2014-12-18 NZ NZ721089A patent/NZ721089A/en unknown
- 2014-12-18 CA CA2933601A patent/CA2933601A1/en active Pending
- 2014-12-18 HU HUE14872684A patent/HUE047062T2/hu unknown
- 2014-12-18 SI SI201432120T patent/SI3607962T1/sl unknown
- 2014-12-18 BR BR112016013961A patent/BR112016013961A2/pt not_active Application Discontinuation
- 2014-12-18 SI SI201431450T patent/SI2986308T1/sl unknown
- 2014-12-18 KR KR1020237012136A patent/KR20230051721A/ko not_active Ceased
- 2014-12-18 KR KR1020167019427A patent/KR102399383B1/ko active Active
- 2014-12-18 RS RS20251135A patent/RS67626B1/sr unknown
- 2014-12-18 LT LTEP19197866.7T patent/LT3607962T/lt unknown
- 2014-12-18 HR HRP20251406TT patent/HRP20251406T1/hr unknown
- 2014-12-18 KR KR1020227004084A patent/KR20220028125A/ko not_active Ceased
- 2014-12-18 DK DK14872684.7T patent/DK2986308T3/da active
- 2014-12-18 JP JP2016539318A patent/JP6824739B2/ja active Active
- 2014-12-18 US US14/575,127 patent/US9220745B2/en active Active
- 2014-12-18 KR KR1020247034828A patent/KR20240154702A/ko active Pending
- 2014-12-18 EP EP19197866.7A patent/EP3607962B1/en active Active
- 2014-12-18 CN CN202011494632.XA patent/CN112546197A/zh active Pending
- 2014-12-18 SM SM20250427T patent/SMT202500427T1/it unknown
- 2014-12-18 PL PL14872684T patent/PL2986308T3/pl unknown
- 2014-12-18 ES ES19197866T patent/ES3055611T3/es active Active
2015
- 2015-11-13 US US14/941,301 patent/US10028995B2/en active Active
2016
- 2016-06-09 IL IL246162A patent/IL246162B/en active IP Right Grant
- 2016-06-17 MX MX2020011190A patent/MX2020011190A/es unknown
2018
- 2018-03-01 US US15/909,617 patent/US10493124B2/en active Active
- 2018-09-19 US US16/135,608 patent/US10765722B2/en active Active
2019
- 2019-04-12 US US16/382,850 patent/US11096983B2/en active Active
- 2019-08-23 JP JP2019153144A patent/JP7175506B2/ja active Active
2020
- 2020-01-13 CY CY20201100026T patent/CY1122604T1/el unknown
- 2020-11-26 AU AU2020277230A patent/AU2020277230A1/en not_active Abandoned
2021
- 2021-07-20 US US17/380,311 patent/US11559559B2/en active Active
2022
- 2022-07-14 JP JP2022113327A patent/JP2022137224A/ja not_active Withdrawn
2023
- 2023-01-23 US US18/157,933 patent/US20230226141A1/en not_active Abandoned
2024
- 2024-09-18 AU AU2024219851A patent/AU2024219851A1/en active Pending
2025
- 2025-05-09 JP JP2025078759A patent/JP2025114753A/ja active Pending

Also Published As

Publication number	Publication date
IL246162B (en)	2020-03-31
MX380968B (es)	2025-03-12
EA037823B1 (ru)	2021-05-25
US20190328827A1 (en)	2019-10-31
AU2014364528A9 (en)	2016-07-28
MX2016008108A (es)	2017-03-09
PT2986308T (pt)	2020-01-21
RS67626B1 (sr)	2026-02-27
US10765722B2 (en)	2020-09-08
JP2019214610A (ja)	2019-12-19
US11559559B2 (en)	2023-01-24
US10028995B2 (en)	2018-07-24
HUE047062T2 (hu)	2020-04-28
HRP20251406T1 (hr)	2026-02-27
LT3607962T (lt)	2026-01-12
KR20220028125A (ko)	2022-03-08
PL2986308T3 (pl)	2020-05-18
CN111920939A (zh)	2020-11-13
DK3607962T3 (da)	2025-11-17
SMT202000018T1 (it)	2020-03-13
ES3055611T3 (en)	2026-02-13
EP2986308A4 (en)	2017-01-11
US20190070250A1 (en)	2019-03-07
WO2015095535A1 (en)	2015-06-25
HRP20200009T1 (hr)	2020-03-20
AU2020277230A1 (en)	2020-12-24
US20180193407A1 (en)	2018-07-12
US20220047669A1 (en)	2022-02-17
US9220745B2 (en)	2015-12-29
JP6824739B2 (ja)	2021-02-03
CN112546197A (zh)	2021-03-26
IL246162A0 (en)	2016-07-31
AU2014364528C1 (en)	2021-01-07
EP2986308A1 (en)	2016-02-24
RS59804B1 (sr)	2020-02-28
EP2986308B1 (en)	2019-10-16
SI3607962T1 (sl)	2026-02-27
AU2014364528B2 (en)	2020-08-27
CN119700926A (zh)	2025-03-28
EP3607962B1 (en)	2025-08-13
EA201691258A1 (ru)	2016-11-30
BR112016013961A2 (pt)	2017-10-10
ES2771749T3 (es)	2020-07-07
EP3607962A1 (en)	2020-02-12
FI3607962T3 (fi)	2025-11-24
SMT202500427T1 (it)	2026-01-12
AU2024219851A1 (en)	2024-10-10
NZ721089A (en)	2022-10-28
CY1122604T1 (el)	2021-03-12
JP2025114753A (ja)	2025-08-05
AU2014364528A1 (en)	2016-06-30
CN106061493A (zh)	2016-10-26
US20160129072A1 (en)	2016-05-12
US10493124B2 (en)	2019-12-03
KR20240154702A (ko)	2024-10-25
PL3607962T3 (pl)	2026-03-09
US20230226141A1 (en)	2023-07-20
LT2986308T (lt)	2020-03-25
US20150164980A1 (en)	2015-06-18
KR20230051721A (ko)	2023-04-18
SI2986308T1 (sl)	2020-03-31
JP2017501154A (ja)	2017-01-12
PT3607962T (pt)	2025-11-18
KR102399383B1 (ko)	2022-05-19
JP7175506B2 (ja)	2022-11-21
KR20160117437A (ko)	2016-10-10
US11096983B2 (en)	2021-08-24
MX2020011190A (es)	2020-11-13
WO2015095535A9 (en)	2016-07-14
DK2986308T3 (en)	2020-01-27
JP2022137224A (ja)	2022-09-21

Legal Events

Date	Code	Title	Description
2019-12-13	EEER	Examination request	Effective date: 20191127
2024-12-13	MFA	Maintenance fee for application paid	Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD Year of fee payment: 10
2024-12-13	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213
2024-12-13	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213
2025-04-16	D15	Examination report completed	Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250416
2025-08-15	P11	Amendment of application requested	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250815
2025-08-19	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250819
2025-10-22	P11	Amendment of application requested	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251022
2025-10-22	P13	Application amended	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251022
2025-12-26	MFA	Maintenance fee for application paid	Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD Year of fee payment: 11
2025-12-26	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251226
2025-12-26	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251226
2026-02-25	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260225

Publication	Publication Date	Title
US11559559B2 (en)	2023-01-24	Angiotensin II alone or in combination for the treatment of hypotension
JP6962943B2 (ja)	2021-11-05	腎不全を処置するための組成物及び方法
HK40050536A (en)	2021-12-31	Angiotensin ii alone or in combination for the treatment of hypotension
HK40039808A (en)	2021-07-23	Angiotensin ii alone or in combination for the treatment of hypotension
HK1229245A1 (en)	2017-11-17	Angiotensin ii alone or in combination for the treatment of hypotension